It's Official: CRIO Sites Are Now 25% Of US Sites On Chronic Condition Studies

CRIO continues to lead the U.S. eSource market, with its platform widely adopted across clinical research sites. A recent analysis of 50 Phase 2 and 3 studies showed that, on average, 28% of U.S. sites were CRIO clients, with even higher adoption in key therapeutic areas. This broad adoption reflects CRIO’s strong presence among larger site networks, which increasingly dominate site selection for trials.

To extend eSource adoption to smaller, independent sites—often lacking resources to implement their own systems—CRIO offers Central eSource. This sponsor-driven solution simplifies adoption by providing pre-built templates, training, and support. Internationally, CRIO is expanding rapidly, with growing site penetration in Canada, Europe, Australia, and Brazil. To support global growth, CRIO is localizing its platform into multiple languages and offering translation APIs to speed study builds. In regions where eSource awareness lags, sponsor-led initiatives like Central eSource can accelerate adoption, improving site engagement, data quality, and trial efficiency worldwide.